{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.3","upperLimit":"23.5","value":"12.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as time of treatment start until death or date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 240mg IV + Ramucirumab 8mg/kg IV\n\nNivolumab: Nivolumab 240mg, IV over 30 minutes.\n\nRamucirumab: 8mg/kg, IV over 60 minutes.","id":"OG000","title":"Nivolumab + Ramucirumab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time of treatment start until death or date of last contact, up to a maximum of 32 months.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}